"CDK2 ANTAGONISTS AS SHORT FORM C-MAF TRANSCRIPTION FACTOR ANTAGONISTS FOR TREATMENT OF GLAUCOMA"
Application 4210/DELNP/2006 published 2007-06-22, filed 2006-07-20
The short form version of c-Maf transcription factor is up-regulated in steroid-treated and transforming growth factor beta2-treated trabecular meshwork cells, and is present at elevated levels in glaucomatous versus normal trabecular meshwork cells and in glaucomatous versus normal optic nerve head tissue. Expression of short form c-Maf transcription factor under these conditions indicates a causal or effector role for the factor in primary open-angle and steroid-induced glaucoma pathogenesis. Antagonism of short form c-Maf transcription factor expression and/or activity in the trabecular meshwork or other ocular tissue is provided for inhibiting or alleviating glaucoma pathogenesis. Antagonists include cyclin-dependent kinase 2 inhibitors.
Applicant
1)ALCON, INC.
:BOSCH 69, P.O. BOX 62, CH-6331 HUNENBERG, SWITZERLAND. Switzerland
Inventor
1)SHEPARD, ALLAN R. 2)JACOBSON, NASREEN 3)CLARK, ABBOT F.
International Info
Classification: A61K 31/52
Publication Number: WO 2005/063252
Application Date: 2004-12-21
Priority Information
60/531,801 U.S.A. 2003-12-22